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Abstract
Aims To evaluate UFT and cyclophosphamide (CTX)
based metronomic chemotherapy plus celecoxib (CXB) for
the treatment of patients with heavily pre-treated advanced
gastrointestinal malignancies.
Methods Thirty-eight patients received 500 mg/mq
2 CTX
i.v bolus on day 1 and, from day 2, 50 mg/day CTX p.o.
plus 100 mg/twice a day UFT p.o. and 200 mg/twice a day
CXB p.o. Tegafur, 5-FU, 5-FUH2, GHB and uracil phar-
macokinetics were assessed. Plasma vascular endothelial
growth factor (VEGF), soluble VE-cadherin (sVE-C) and
thrombospondin-1 (TSP-1) levels were detected by ELISA
and real-time PCR of CD133 gene expression on peripheral
blood mononuclear cell was also performed.
Results Seventeen patients (45%) obtained stable disease
(SD) with a median duration of 5.8 ms (range, 4.2–7.4).
Median progression free survival (PFS) and overall sur-
vival (OS) were 2.7 ms (95% CI, 1.6–3.9 ms) and 7.1 ms
(95% CI, 4.3–9.9 ms), respectively. No toxicities of grade
[1 were observed. Pharmacokinetics of 27 patients (13/14,
SD/progressive disease, PD) after the ﬁrst treatment of
UFT revealed that 5-FU AUC and Cmax values greater than
1.313 h 9 lg/ml and 0.501 lg/ml, respectively, were sta-
tistically correlated with stabilization of disease and pro-
longed PFS/OS. VEGF and sVE-C plasma levels were
greater in the PD group when compared to SD group.
CD133 expression increased only in the PD patients.
Conclusion Metronomic UFT and CTX with CXB in
heavily pre-treated gastrointestinal patients were well tol-
erated and associated with interesting activity. Potential
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Introduction
Interest in metronomic chemotherapy is rapidly growing
among both basic researchers and clinical oncologists,
especially because of its efﬁcacy in palliative care, low
toxicity proﬁle [1] and low cost when using off patent
drugs [2]. However, rational strategies for developing new
metronomic chemotherapy protocols and schedules are
needed in order to improve the knowledge and application
of this therapeutic regimen. The antitumor effects of met-
ronomic chemotherapy can be achieved through several
mechanisms, including inhibition of angiogenesis and
vasculogenesis, blockade of circulating endothelial pro-
genitor cells (CEPs) [3], suppression of HIF-1a expression
[4, 5] and, depending on the administered drug and tumor
cells being treated, cytotoxic action on tumor cells and
stimulation of the immune system [6]. Metronomic che-
motherapy has also been proposed as a promising approach
to treat patients resistant to standard chemotherapies [7, 8].
Metronomic administration of cyclophosphamide (CTX) in
combination with antiangiogenic drugs has shown a potent
preclinical activity [9]. Indeed, phase II studies evaluating
the impact of metronomic CTX in combination with
celecoxib (CXB), a selective cyclooxygenase-2 inhibitor,
showed promising antitumor activity [10]. Moreover,
celecoxib has been shown to inhibit tumor angiogenesis
[11] in preclinical studies, and to induce apoptosis of
endothelial cells in tumors of the gastrointestinal tract [12].
UFT, a combination of tegafur, a prodrug of 5-ﬂuoro-
uracil (5-FU) and uracil, has demonstrated clinical anti-
tumor activity in many malignancies and, in particular, for
the treatment of gastrointestinal cancers [13–15]. It has
been successfully tested using metronomic-like protocols
in randomized phase III adjuvant therapy trials of non
small cell lung cancer [16] and breast cancer [17] where the
drug has taken orally every day for 2 years with no breaks.
Furthermore, gamma-hydroxybutyric acid (GHB), a
metabolite of UFT, has shown antiangiogenic activity in
preclinical studies [18]. The rationale of a metronomic
chemotherapy strategy based on the combination of UFT
and CTX derives in part from their synergistic antitumor
activity in mouse models of advanced metastatic disease
[19] and also because of evidence that CTX may alter the
expression of enzymes such as thymidylate synthase (TS)
and dihydropyrimidine dehydrogenase (DPD) in tumor
cells in such a way as to render them more sensitive to
5-FU [20]. Given these considerations, we planned a phase
II clinical study to evaluate the feasibility and the activity
of a regimen combining metronomic UFT plus CTX and
CXB in patients with advanced metastatic gastrointestinal
cancers, mainly metastatic colorectal carcinoma (mCRC),
who failed standard therapies with an acceptable life
expectancy. The primary objective of the study was to
assess the proportion of patients free from progression at
2 months from the beginning of the treatment. Secondary
endpoints were a series of pharmacodynamic and phar-
macokinetic analyses such as the investigation of the
pharmacokinetic parameters of UFT and its metabolites
and the modulation of CD133 gene expression, vascular
endothelial growth factor (VEGF), soluble VE-cadherin
(sVE-C) and thrombospondin-1 (TSP-1) plasma levels as
possible pharmacokinetic/pharmacodynamic markers of
the therapy.
Patients and methods
Patient selection
Main eligibility criteria included: (1) histologically con-
ﬁrmed diagnosis of colorectal or other gastrointestinal
adenocarcinoma with metastatic disease; (2) previous che-
motherapy with ﬂuoropyrimidines, oxaliplatin, irinotecan,
whenindicated;(3)measurabledisease progressing duringor
within 3 months from the end of the treatments; (4) life
expectancy greater than 3 months; (5) Eastern Cooperative
Oncology Group performance status B 2; (6) adequate bone
marrow, renal and liver function (leukocytes C3,000 mm
-3,
platelet C100,000 mm
-3, creatinine B2m g / d L
-1,t o t a lb i l -
irubin B 1.5x institutional upper limit of normal, AST/ALT
B 5x institutional upper limit of normal). Study exclusion
criteria were as follows: brain metastasis, symptomatic car-
diac disease, recent myocardial infarction, active infections
and inﬂammatory bowel disease.
Treatment schedule and doses
Patients received on day 1 a single administration of CTX
500 mg/m
2 as i.v. bolus and, from day 2, 50 mg CTX p.o.
once daily plus 100 mg UFT p.o. and 200 mg CXB p.o.
twice a day. From day 2, the treatment was continued
without interruption until either disease progression,
unacceptable toxicities, deterioration of performance sta-
tus, or patient refusal to continue treatment. No dose
reduction for toxicities was applied. To prevent nausea and
vomiting, metoclopramide 10 mg i.v plus dexamethasone
4 mg i.v. were administered before CTX i.v. chemotherapy
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123on day 1. Loperamide 2 mg orally every 2 h and oral
rehydration were prescribed in the event of delayed diar-
rhea. No prophylactic treatment with supportive cytokines
such as G-CSF was recommended.
Clinical assessment, toxicity and response criteria
Pretreatment evaluation included complete history and
physical examination, performance status assessment, com-
plete blood count and differential, platelet count, complete
blood proﬁle, tumor markers, urinalysis, ECG, chest X-ray
or computed tomography scan, abdominal computed
tomography scan and/or sonogram, and any other appro-
priate diagnostic procedure to evaluate metastatic sites.
During treatment, a physical examination, a complete blood
cell count, blood proﬁle, urinalysis and toxicity evaluation
were performed every 3 weeks. Sites of metastatic disease
were radiologically re-evaluated every 2 months, according
to the RECIST criteria [21]. A chest X-ray and/or an
abdominal sonogram were repeated at least every 6 months
if there was no evidence of lung or abdominal disease,
respectively. Toxicities were scored according to the stan-
dard NCI Common Terminology Criteria for Adverse
Events (version 3.0). Duration of responses was calculated
from the ﬁrst day of treatment to the date of ﬁrst observation
of progressive disease or last examination.
Pharmacokinetics of tegafur, 5-FU, 5-ﬂuoro-5,6-
dihydrouracil (5-FUH2), GHB and uracil
The pharmacokinetic analysis of tegafur, 5-FU, 5-FUH2, GHB
and uracil were performed as previously described [22–24]
with minor modiﬁcations. Blood samples (4 ml each) for
pharmacokinetic assays were taken from an indwelling i.v.
cannula placed in an antecubital vein at baseline, 30 min, 1,
1.5,2, 3 and 5 h at day 1, 28 and 56 after the beginning of UFT
oral administration. Blood was centrifuged (5 min, 4,000 rpm,
4C) to separate plasma, which was stored at -80Ca n d
assayed within 1 week. The simultaneous assay of 5-FU and
5-FUH2 in human plasma was performed by a validated,
nonradioactive reverse-phase HPLC method with ultraviolet
detection. Brieﬂy, 0.5 ml of plasma, mixed with sodium ace-
tate and sodium sulfate, were extracted with 7 ml of n-propyl
alcohol/diethyl ether. Samples were centrifuged to separate the
organic phase, which was evaporated to dryness; they were
then reconstituted with 250 ll of mobile phase (50 mmol/l
potassium phosphate; pH 4.0) and ﬁnally injected into the LC
Module I Plus HPLC with an ultraviolet detector set at 215 nm
(Waters, Milford, USA). 5-FU and 5-FUH2 were separated on
Hypersil BDS C18 stationary phase (Alltech, Deerﬁeld, USA),
eluted with 1 ml/min of mobile phase. The data analysis was
performed by use of Millenium 2.1 software (Waters). Stan-
dard calibration curves were obtained by adding 5-FU and
5-FUH2 to 0.5 ml of blank plasma obtained from healthy
donors on each day of analysis, resulting in ﬁnal concentra-
tions that ranged from 0.08 to 75 lg/ml. For the analysis of
tegafur (FT) and uracil (U), plasma samples (1.0 ml) were
adjusted with 0.1 ml of 0.5 M NaH2PO4 buffer and 8 ml ethyl
acetate were added. After extraction and centrifugation, the
organic layer was removed and evaporated under N2 at 50C.
The residue was dissolved in 50 ll of methanol, and 20 ll
were injected into the HPLC with an ultraviolet detector set at
270 nm (Waters, Milford, USA). FT and U were separated on
Hypersil BDS C18 stationary phase (Alltech, Deerﬁeld, USA),
eluted with 1 ml/min of mobile phase. The data analysis was
performed by use of Millenium 2.1 software (Waters). Mobile
phase was 0.01 M sodium acetate buffer (pH 4):methanol
(85:15, v/v) as eluent. The retention times were 6.4, 2.7 min
for FT and U, respectively. Standard calibration curves were
obtained by adding FT and U to 0.5 ml of blank plasma
obtained from healthy donors one a c hd a yo fa n a l y s i s .S e n s i -
tivity limit of quantitative analysis in plasma was 0.1 lg/ml. In
order to detect GHB, 200 ll of plasma were treated with
500 ll of acetonitrile, using a -hydroxy-isovaleric acid
(200 ng/ml) as internal standard. After agitation and centri-
fugation (9,000g for 10 min), the supernatant was collected
and evaporated to dryness under nitrogen ﬂow. The residue
was derivatized by adding 50 ll N,O-bis(trimethylsilyl)triﬂu-
oroacetamide ? 1% trimethylchlorosilane (BSTFA ? 1%
TMCS), then incubated for 30 min at 70C. An aliquot (1 ml)
of the derivatized extract was directly injected into GC/MS
using a TRACE gas chromatograph equipped with a Polaris
Q as mass detector and an AS2000 as autosampler (Thermo
Finnigan, Rodano, Italy). The ﬂow of carrier gas (helium,
purity grade N55) through the column (Restek, Palo Alto,
USA; Rtx-5MS capillary column, 30 m 9 0.25 mm 9
0.25 lm ﬁlm thickness) was 1.0 ml/min. The injector tem-
perature was 280C and splitless injection was employed
with a split valve off-time of 1.0 min. The column oven
temperature was programmed to rise from an initial tem-
perature of 65C, maintained for 1 min, to 140Ca t2 2 C/
min, then 140Cf o r3m i n ,t h e nt o2 9 0 Ca t5 0 C/min and
maintained at 290C for the ﬁnal 5 min. Data were recorded
in full scan and ions monitored were: m/z 233,7 3a n d1 4 7
and m/z 73, 145 and 219 for GHB and a-hydroxy-isovaleric
acid, respectively (the underlined ions were used for
quantitation).
Individual plasma concentration proﬁles of tegafur and
its catabolites were ﬁtted according to a two-compartment
model by use of nonlinear least squares regression analysis
(MwPharm software, version 3.60; MediWare, Groningen,
The Netherlands). The area under the curve (AUC) of
tegafur, 5-FU, 5-FUH2, GHB and uracil was calculated by
the trapezoidal method for the area from time 0 to the time
of the last measurable concentration. The maximum
plasma concentration (Cmax) and time to reach Cmax (Tmax)
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123were identiﬁed from the inspection of tegafur and its
catabolite concentration–time plots.
CD133 gene expression by real time RT-PCR
in peripheral blood mononuclear cells (PBMCs)
Before drug administration and at day 28, 56, 84 and 112,
10 ml of blood were drawn from the antecubital vein of
patients. PBMCs were collected as previously published
[7]; the resulting pellet was immediately frozen in liquid
nitrogen and stored at -80C. As previously described
[25], RNA was reverse transcribed and the resulting cDNA
was diluted and then ampliﬁed by QRT-PCR with the
Applied Biosystems 7900HT sequence detection system.
CD133 validated primer were purchased from Applied
Biosystems (Assay ID Hs00195682_m1). The PCR thermal
cycling conditions and optimisation of primer concentra-
tions were followed as per manufacturer’s instructions.
Ampliﬁcations were normalized to GAPDH and the
quantitation of gene expression was performed using the
DDCt calculation; the amount of CD133, normalized to the
endogenous control and relative to the calibrator (PBMC
sample at day 0), is given as 2DDCt. The data are presented
as the percentage of 2DDCt at day 0 (before the beginning
of metronomic schedule).
Plasma VEGF, TSP-1 and sVE-C levels detection
by ELISA
Plasma samples obtained at the same days of PBMC col-
lection were assessed for VEGF, TSP-1 and sVE-C levels
using commercially available ELISA kits. Each sample was
assayed for human VEGF and TSP-1 concentrations by the
ELISA Kit Quantikine
 (DVE00 and DTSP10, R&D Sys-
tems, Minneapolis, MN, USA) and for soluble VE-cadherin
by Instant ELISA Kit (Bender Medsystems, Wien, Austria).
Measurements were performed by the microplate reader
Multiskan Spectrum (Thermo Labsystems, Milan, Italy) set
to 450 nm (with a wavelength correction set to 540 nm).
Statistical analysis
The primary objective of the study was to evaluate the
percentage of patients not progressed within 2 months from
the beginning of metronomic CTX plus UFT and celecoxib
regimen. In phase II studies of chemotherapy administered
for palliation in patients with mCRC or with gastrointes-
tinal tumors, already treated with standard chemotherapy
treatments, a rate of approximately 20% of patients free
from progression within 2 months of treatment was gen-
erally observed. Our study of metronomic UFT plus CTX
and CXB aimed to achieve an increase from 20 to 40% in
the proportion of patients not progressed at 2 months from
starting treatment.
According with the single-stage design described by
FlemingandA’Hern,choosingaparameterP0(percentageof
patients free from progression at 2 months: null hypothe-
sis) = 0.20, and P1 (proportion of patients free from pro-
gression at 2 months: alternative hypothesis) = 0.40, and
considering the errors a and b of 0.10 and 0.10, the study
requiredtheenrollmentofatleast36evaluablepatients.Study
treatment was considered promising when atleast 11 patients
were progression free at 2 months. Progression free survival
(PFS)andoverallsurvival(OS)werecalculatedfromthedate
of progression or death/loss to follow-up, respectively, using
the Kaplan–Meier method. The log-rank test was used to
comparesurvivalbetweenpatientshavingstabledisease(SD)
andprogressivedisease(PD).StatisticalanalysisbyANOVA,
followed by the Student–Newman–Keuls test, was used to
assess the statistical differences of pharmacokinetic and
pharmacodynamic data. Correlations between pharmacoki-
netic parameters were investigated by linear regression anal-
ysis. Cut off values for 5-FU Cmax and AUC parameters were
found with nonparametric receiver operating characteristic
(ROC) analysis, performed to assess the accuracy of phar-
macokinetic parameters to discriminate between stable and
progressive disease groups of patient. Statistical analyses
were performed using the GraphPad Prism software version
5.0 (GraphPad Software Inc., La Jolla, CA, USA).
Results
Patients and toxicity
As outlined in Table 1, mainly patients with advanced met-
astatic colorectal cancer (mCRC; n = 30) were entered into
the study. The ﬁnal analysis was conducted on the total
number of 38 patients. Median age was 71 years (range,
51–87 years), ECOG performance status was 0–1 in 37
patientsand 2 inone.Asreported, the entirestudy population
was heavily pretreated and in particular oxaliplatin- and
ﬂuoropyrimidines-based chemotherapy was administered to
all patientswithmCRC.Ofnote, 36and 20% ofpatients with
mCRC received in addition cetuximab and bevacizumab,
respectively. Patients with mCRC received a median number
ofthree treatments(range2–5)beforeentering thestudy.The
patient with gastric cancer received a ﬁrst-line including
oxaliplatin and 5-ﬂuorouracil and the remainder of the
patients received at leasta chemotherapy treatment including
gemcitabine. The patients with gastrointestinal cancers
received a median number of treatments of two. A median of
12 weeks per patient (range, 2–63 weeks) of therapy were
administered using metronomic schedule. Cessation of
treatment was due to disease progression in all patients.
278 Angiogenesis (2012) 15:275–286
123All patients were assessable for toxicities, which were
very uncommon. In particular, we did not observe any
toxicities higher than grade 1. Four (10.5%) and six
patients (15.7%) experienced, respectively, a transient
grade 1 diarrhea and nausea, which resolved without
interrupting the treatment. No notable hematological tox-
icities were observed.
Antitumor activity and survival
All patients had at least a measurable lesion according to
Response Evaluation Criteria in Solid Tumors (RECIST)
criteria [21]. Of 38 patients assessable for response, we
observed17patients(45%)withstabledisease(SD),thatlasted
a median period of 5.8 months (range, 2.5–14.6 months), and
21 patients (55%) with progression of disease (PD) at the ﬁrst
clinical evaluation. Among mCRC patients, thirteen (43%)
obtained a stabilization of disease that lasted a median period
of 5.1 months (range, 2.8–14.1 months) with an observed
median overall survival in the responders of 12.1 months
(range, 5–14 months). The median duration of SD response in
the remaining four non-CRC patients (2 patients with pancre-
atic cancer, one patient with cancer of the biliary tract and one
patient with hepatocellular carcinoma) was 5.6 months (range,
2.4–8.9 months).Afteramedianfollow-upof18.3 months,for
the entire population median progression free survival and
median overall survival were 2.7 months (95% CI,
1.6–3.9 month; Fig. 1a) and 7.1 months (95% CI,
4.3–9.9 months; Fig. 1b), respectively.
Pharmacokinetics
The pharmacokinetic analyses of tegafur, 5-FU, 5-FUH2,
uracil and GHB were performed in 27 patients (21 patients
with colon cancer, 2 patients with pancreatic cancer, 2
patients with cancer of the biliary tract and 2 patients with
hepatocellular carcinoma). A statistically signiﬁcant dif-
ference in the values of area under curve (AUC) and
Table 1 Patient characteristics
Number of patients 38
Median age (range) 71 years (51–87)
Gender (male/female) 25 (66%)/13 (34%)
PS ECOG (0/1/2) 13 (34%)/24 (63%)/
1 (3%)
Primary tumor sites n (%)
Colon-rectum 30 (79%)
Gastric 1 (3%)
Pancreas 2 (5%)
HCC 2 (5%)
Biliary tract 3 (8%)
Metastatic sites n (%)
Liver 26 (68%)
Lung 24 (63%)
Lymph node 14 (37%)
Bone 4 (10%)
Peritoneum 6 (16%)
Others 9 (24%)
No. of metastatic sites (%)
Single 7 (19%)
Multiple 31 (81%)
No. of previous cancer treatments for mCRC
median (range)
3 (2–5)
Drugs previously used for the treatment of mCRC
Oxaliplatin 30 (100%)
Irinotecan 27 (90%)
Fluoropyrimidine 30 (100%)
Cetuximab 11 (36%)
Bevacizumab 6 (20%)
PS ECOG performance status Eastern Cooperative Oncology Group,
mCRC metastatic colorectal cancer
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Fig. 1 Progression free survival (a) and overall survival (b) curves
calculated by the Kaplan–Meier method from the ﬁrst day of the
metronomic CTX, UFT and CXB schedule
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123maximum plasma concentration (Cmax) on day 1 compared
to day 28 and day 56 of tegafur was found (data not
shown). Among the numerous data obtained by the com-
parison of the pharmacokinetic parameters of PD (n = 14)
and SD (n = 13) patients, statistically signiﬁcant differ-
ences were demonstrated in 5-FU AUC values both on day
1 and day 28 (data not shown). Moreover, the difference of
5-FU Cmax values on day 1 between the group of patients in
PD and SD patients was found to be statistically signiﬁcant
(Fig. 2). The analysis of 27 patients, after the ﬁrst intake of
100 mg UFT tablet, revealed a signiﬁcant difference
between the PD and SD group at day 1 for the 5-FU AUC
(0.997 ± 1.271 vs. 2.765 ± 1.709 h 9 lg/ml, respectively,
P\0.05; and Cmax (0.453 ± 0.573 vs. 1.134 ± 0.749 lg/
ml, respectively, P\0.05).
Cut off values for 5-FU AUC and 5-FU Cmax parameters
higher than 1.313 h 9 lg/ml and 0.501 lg/ml, respec-
tively, could predict the clinical stabilization of the disease
at day 1 with a sensitivity of 81.82% and a speciﬁcity of
69.23 and 76.92%, respectively. Even more interesting,
patients with the 5-FU AUC and Cmax pharmacokinetic
parameters at day 1 greater than 1.313 h 9 lg/ml and
0.501 lg/ml, respectively, showed a signiﬁcant prolonged
PFS (Fig. 3a, b) and a signiﬁcant increase of the OS
(Fig. 3c, d).
Pharmacodynamics
The pharmacodynamic analyses were performed in 35
patients. After starting the metronomic schedule, the
VEGF-A and sVE-C plasma levels remained markedly
greater (but not statistically signiﬁcant) in the PD (n = 19)
group of patients when compared to the SD (n = 16) group
of patients (Fig. 4a, b, respectively). Interestingly, the
measurement plasma levels of endogenous TSP-1 during
the time (measured by the TSP-1 AUC) was signiﬁcantly
higher in SD than PD patients (Fig. 5a). After the begin-
ning of the metronomic treatment, a lower CD133 gene
expression was consistently maintained in the SD patients
and resulted similar to the baseline observation. Patients
with progressive disease showed a substantial increase of
CD133 gene expression after 4 weeks from the beginning
of treatment, maintaining these high levels for at least
4 months (Fig. 5b).
Discussion
The primary objective of the study was to assess whether a
metronomic chemotherapy regimen including UFT plus
CTX and CXB could increase the progression-free survival
at 2 months in a population of metastatic gastrointestinal
cancer patients already treated with several chemotherapy
lines. The observed results showed that more than 40% of
patients were free of disease progression at 2 months from
the beginning of the treatment with a median progression
free survival and a median overall survival, respectively of
2.7 and 7.1 months. The results seem suggest a possible
antitumor activity of this metronomic regimen, comparable
with those observed in the same setting of patients treated
with other third/fourth lines of chemotherapy.
Previous clinical experiences have showed that sub-
sequent treatments to a ﬁrst–second line of chemotherapy,
generally still including a ﬂuoropyrimidine, in this setting of
refractory patients, produce a poor response rate (generally
less than 10%), with a low median progression free and a
median overall survival, generally around a few months [26].
Furthermore, a high percentage of patients were reported to
experience severe toxicity (Cgrade 3 of NCI scale), further
limiting the use of these regimens [27, 28]. Our results con-
ﬁrm, instead, the previous published reports and experience
regarding the generally excellent tolerability proﬁle of met-
ronomic chemotherapy, which basically does not show
treatment-relatedtoxicitygreaterthangrade I–IIaccordingto
the NCI scale, as previously shown in cancer patients with
advanced colorectal cancer [7], prostate cancer [29, 30],
breast cancer [31–33], and gastrointestinal cancer [10]. Apart
from the well-known low toxicity of metronomic chemo-
therapy,anotherpossibleexplanationforthegoodtolerability
of our schedule could be found in the co-administration of
celecoxib. Indeed, Lin EH et al. [34] have shown a potential
beneﬁt for the toxicity proﬁle of capecitabine if this ﬂuoro-
pyrimidine was associated with celecoxib. Celecoxib may
improve clinical outcomes and reduce toxicities (e.g. the
gastrointestinal ones) when administered in association with
a 5-FU prodrug such as UFT.
With particular reference to mCRC patients, who rep-
resented the 79% of the whole study population (30
patients), although no complete or partial responses were
observed, the metronomic UFT/CTX and CXB combina-
tion produced a stable disease in the 43% of patients that
lasted a median period of 5.1 months, with an observed
median overall survival in the responders of 12.1 months
(range, 5–14 months). These preliminary results, for the
ﬁrst time, suggest a possible role of this metronomic reg-
imen in a population of treated refractory mCRC patients.
No previous clinical experiences have been reported for
a metronomic regimen including UFT/CTX and CXB in
mCRC patients and, in general, metronomic chemotherapy
has been poorly evaluated in this setting. A few papers are
currently published in the scientiﬁc literature. Young et al.
[10] evaluated the impact of a combination metronomic
treatment with CTX, vinblastine and rofecoxib in patients
with advanced tumours, including only 13 with mCRC
patients, observing a partial response in one patient and a
stable disease in other patients with a progression free
280 Angiogenesis (2012) 15:275–286
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Fig. 2 Plasma levels of Tegafur, 5-ﬂuorouracil (5-FU), 5-ﬂuoro-5,6-
dihydrouracil (5-FUH2), Uracil and gamma-hydroxybutyric acid
(GHB) in 13 stable disease (SD) patients and 14 progressive disease
(PD) patients at day 1, 28 and 56, receiving the metronomic CTX,
UFT and CXB schedule. Points mean; bars Standard Deviation.
*P\0.05 PD versus SD;
#P\0.01 PD versus SD
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123survival of 12 and 7 months, respectively. Moreover, in a
recent phase II randomized study of 88 patients with dif-
ferent cancer types, 11 mCRC patients were included and
treated with CTX metronomic, showing only disease pro-
gressions [35].
In light of these results, this minimally toxic metro-
nomic regimen with UFT, CTX and CXB could represent a
possible therapeutic option for patients with mCRC who
have failed chemotherapies with or without target thera-
pies. Furthermore, remarkable results are represented by
pharmacokinetic and pharmacodynamic data that show a
possible correlation between these laboratory analyses and
antitumor activity of the treatment. Various tegafur-based
schedules have been evaluated in a large number of phase
II and III studies; the investigated doses varied from 300 to
600 mg/m
2/day [36]. A standard UFT schedule have been
published by Shirao et al. [37] in advanced colorectal
cancer with a recommended dose of tegafur 300 mg/m
2
daily, combined with leucovorin 75 mg/day for 28 days
with subsequent courses repeated after 7-days intervals.
Metronomic chemotherapy is a frequent (even daily),
prolonged low dose administration of a chemotherapeutic
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123drug, thus we have decided to design our study based on
the prolonged oral administration of tegafur at a ﬁxed dose
of 100 mg twice a day which is approximately one third of
the published, standard, daily total dose.
Astrongrationaleofametronomicchemotherapybasedon
the association between UFT and CTX derives directly from
their synergistic antitumor activity in experimental mouse
modelsofmetastaticbreastandhepatocellularcarcinoma[19,
38]. The clinicalcombination of UFT and CTX has also been
evaluated in women with metastatic breast cancer, although
not at a metronomic dosing, by Ogawa et al. [39] who found
that daily treatment with UFT (300–400 mg) and CTX
(100–150 mg), both given orally, was associated with a 35%
responserate.Arelevantﬁndingofourstudyarerelatedtothe
possible use, in future prospective clinical studies, of UFT
pharmacokineticparametersattheveryﬁrstintakeofthedrug
in order to predict the efﬁcacy and the PFS and OS of our
patients. Indeed, the pharmacokinetic analysis of 27 patients
after the ﬁrst intake of UFT revealed a signiﬁcant difference
between the PD and SD groups at day 1 in 5-FU (the main
tegafur active metabolite) AUC and Cmax. The data obtained
by means of ROC analysis on both parameters may suggest
that patients with 5-FU AUC and Cmax higher than
1.313 h 9 lg/ml and 0.501 lg/ml have greater clinical ben-
eﬁt from metronomic chemotherapy accompanied by a pro-
longed PFS and OS. Although promising, further studies
should be performed in order to validate our preliminary
ﬁndings. Indeed, a perfect separation between PD and SD
groupsbyROCanalysisisrare,asalsoreportedbyZweigand
Campbell[40],becausethedistributionofthetestresultstend
to overlap. Despite the limitation of this analysis, our results
aretheﬁrstattempttoidentifyapharmacokineticcut-offvalue
in a clinically relevant population. Interestingly, the found
5-FU concentrations are far less from those that could be
achieved by standard 5-FU chemotherapeutic schedules [41]
whichprimarilytargettumorcells.Moreover,inpatientswho
are heavily pre-treated, and whose tumor are resistant to ﬂu-
oropyrimidines, the concentrations detected would not be
expected to exert a direct cytotoxic effect. Indeed, it is plau-
sible to suggest a different mechanism of action of metro-
nomicUFT,perhapsmorerelatedtotheantiangiogeniceffect
on proliferating endothelial cells or circulating endothelial
precursors (CEPs) caused by low concentration of 5-FU. The
anti-angiogenic effects of UFT are ampliﬁed when adminis-
tered at lower, non toxic daily doses [19]. Preclinical studies
have demonstrated that GHB and gamma-butyrolactone
(GBL), active metabolites of UFT, are involved in the
expression of anti-angiogenic activity of UFT [42, 43]. In
particular, in vitro studies have shown that GHB inhibits
endothelial cells with IC50 values of 25.8 ng/ml. In our
experimental setting, the mean plasma GHB Cmax varied
during the treatments from 161 to 127 ng/ml. These concen-
trations are consistent with previous published experience
[44] and, above all, with a direct antiangiogenic activity of
GHB that could synergize with low 5-FU concentrations.
The hypothesis that our metronomic UFT/CTX and
CXB combination schedule could be active through a
marked antiangiogenic activity is also supported by the
pharmacodynamic markers we investigated. Indeed, using
a quantitative reverse transcription-PCR approach for
CD133 RNA evaluation, we have found that this marker
increased during the treatment only in the PD group of
patients. CD133/prominin-1 is expressed on several prim-
itive cells such as hematopoietic stem and progenitor cells
derived from bone marrow, fetal liver and peripheral blood,
and developing epithelium, including circulating endothe-
lial progenitor cells (CEPs) [45]. Moreover, previously
published studies have suggested the role of this protein as
a marker of cancer stem cells in metastatic colorectal
cancer [46, 47]. Lower expression of CD133 in SD patients
might be linked also to a reduced CEP mobilization caused
by metronomic chemotherapy [48, 49], and consequently
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123to a better response to the therapy as CD133-positive cells
are associated with chemoresistance [50]. Although it is not
possible to ascribe with certainty the found CD133
expression in PBMC to CEPs or to other progenitor cells,
our ﬁndings may cautiously represent a possible future
molecular biomarker of metronomic chemotherapy.
Moreover, VE-C, a protein involved in the process of
tumor vascularization [51] and associated with bone mar-
row–derived CEPs [52], showed lower variation of plasma
concentrations in SD patients when compared to PD
patients, suggesting a possible relationship between circu-
lating VE-C levels and activity of the metronomic protocol.
Indeed, a lower increase of VE-C gene expression was also
demonstrated during the treatment with a cyclophospha-
mide-based metronomic schedule in responder patients
with metastatic prostate cancer [30]. Finally, we have
found that SD patients showed a signiﬁcant higher expo-
sure to the endogenous antiangiogenic factor TSP-1 during
treatment with lower plasma VEGF levels when compared
with the PD patients. These results are consistent with the
reported upregulation of TSP-1 as one of the mechanisms
of action of metronomic low-dose chemotherapy regimens
[53].
In conclusion, our results show that metronomic UFT/
CTX chemotherapy with CXB is feasible, well tolerated
and associated with a promising antitumor activity in
heavily pretreated gastrointestinal cancer patients. Signiﬁ-
cant differences in pharmacokinetic parameters were found
between SD and PD patients suggesting the presence of
potentially promising predictive markers for further studies
(disease-oriented) to determine optimal UFT doses at the
very beginning of the treatment, thus improving the
patient’s beneﬁt, including survival.
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